Immunity inducer

Patent metadata

Field	Value
Publication number	US-10994007-B2
Application number	US-201615363748-A
Country	US
Kind code	B2
Filing date	Nov 29, 2016
Priority date	Nov 30, 2015
Publication date	May 4, 2021
Grant date	May 4, 2021

Abstract

Disclosed is an immunity inducer. The immunity inducer comprises virus like particles; the virus like particles comprise a virus-derived outer coat protein and an antigen-bound protein comprising an exogenous antigen; the outer coat protein constitutes an outer coat of the virus like particles, and the antigen-bound protein is comprised in the outer coat; and the virus like particles induce an immune effect of a living body on the antigen.

First claim

What is claimed is:

1. A method of inducing immunity of a living body;
comprising:
(1) administering a pharmacologically effective amount of an immunity inducer to the living body, and
(2) inducing in said living body, by said administration, an immune response against the exogenous antigen,
wherein the immunity inducer comprises virus like particles;
wherein the virus like particles comprise an outer coat protein constituting an outer coat of the virus like particles, and further comprise an antigen-bound protein comprising an exogenous antigen, wherein the virus like particles are virus like particles in which the amino acid sequence of the exogenous antigen is not inserted within the amino acid sequence of the outer coat protein, but the exogenous antigen is present inside the outer coat, and

wherein the administering step is conducted by oral administration, transmucosal administration, parenteral administration, or transdermal administration,
wherein the exogenous antigen is selected from the group consisting of: antigens from pathogens; and cancer antigens,
wherein the exogenous antigen is not exposed on the outer surface of said virus like particles,
wherein in the inducing step, a CTL and an antibody against the exogenous antigen are induced,
wherein the outer coat protein is VP1 of SV40, and
wherein the antigen-bound protein is a fusion protein of the exogenous antigen and an inner peptide, and the inner peptide is VP2 of SV40 and/or VP3 of SV40.

2. The method according to claim 1 , wherein the amino acid sequence of the inner peptide comprises the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 11.

3. The method according to claim 1 , wherein the immunity inducer is a solid preparation, a semisolid preparation, a liquid preparation, an injection, or a suppository.

4. The method according to claim 1 , wherein the amino acid sequence of the VP1 comprises the amino acid sequence of SEQ ID NO: 2.

5. The method according to claim 1 , wherein
the amino acid sequence of the VP1 comprises the amino acid sequence of SEQ ID NO: 2,
the amino acid sequence of the VP2 comprises the amino acid sequence of SEQ ID NO: 11, and
the amino acid sequence of the VP3 comprises the amino acid sequence of SEQ ID NO: 9.

6. A method of inducing immunity of a living body; comprising:
(1) administering a pharmacologically effective amount of an immunity inducer to the living body, and
(2) inducing in said living body, by said administration, an immune response against the exogenous antigen,
wherein the immunity inducer comprises virus like particles;
wherein the virus like particles comprise an outer coat protein constituting an outer coat of the virus like particles, and further comprise an antigen-bound protein comprising an exogenous antigen, wherein the virus like particles are virus like particles in which the amino acid sequence of the exogenous antigen is not inserted within the amino acid sequence of the outer coat protein, but the exogenous antigen is present inside the outer coat, and
wherein the administering step is conducted by oral administration, transmucosal administration, parenteral administration, or transdermal administration,
wherein the exogenous antigen is selected from the group consisting of: antigens from pathogens; and cancer antigens,
wherein the exogenous antigen is not exposed on the outer surface of said virus like particles,
wherein in the inducing step, a CTL and an antibody against the exogenous antigen are induced,
wherein the outer coat protein is VP1 of SV40, and
wherein the antigen-bound protein is a fusion protein of the exogenous antigen and an inner peptide, and the inner peptide is VP2 of SV40.

7. The method according to claim 6 , wherein the amino acid sequence of the VP1 comprises the amino acid sequence of SEQ ID NO: 2.

8. The method according to claim 6 , wherein
the amino acid sequence of the VP1 comprises the amino acid sequence of SEQ ID NO: 2, and
the amino acid sequence of the VP2 comprises the amino acid sequence of SEQ ID NO: 11.

Assignees

• Handa Hiroshi
• Univ Saitama Medical
• Sysmex Corp

Inventors

• Handa Hiroshi
• Kawano Masaaki
• Kato Masahiko

Classifications

• A61K2039/5256

  expressing foreign proteins · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title

• C12N2710/22034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title